MedTrace Logo

Therapeutic Response Evaluation by CTC Expansion System

NCT04972461 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-10-31

No results posted yet for this study

Summary

Among biomarkers, CTCs are a convenient, sensitive and biologically informative option. CTC detection could be considered a real-time "liquid biopsy" approach and contains several advantages such as minimally invasive, easy and safe to perform, and multiple samples can be taken over time, better prognosis to indicate an elevated risk of metastases, improved therapy monitoring, providing live disease status information., However, the number of CTCs is very low, so the establishment of cell culture from CTCs becomes the most challenging over the past year. In this study, we develop a short-term CTC expansion protocol combined with a new surface coating technique. Expanded circulating tumor cells will provide genetic information and develop oncology drug screening platform, which provides an opportunity to monitor response to therapy noninvasively.

Conditions

  • Circulating Tumor Cells

Sponsors & Collaborators

  • Taipei Medical University Hospital

    lead OTHER

Principal Investigators

  • Long-Sheng Lu, MD, Ph.D. · Taipei Medical University Hospital

  • Jeng-Fong Chiou, MD, Ph.D. · Taipei Medical University Hospital

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-08
Primary Completion
2019-08-07
Completion
2023-08-07

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04972461 on ClinicalTrials.gov